Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ocaliva PBC Uptake May Be Slow, But Builds Capital For NASH

Executive Summary

Whether initially gradual or immediately strong, the uptake by physicians of Intercept Pharmaceuticals Inc.'s Ocaliva (obeticholic acid), which was priced at $69,350 per year, will ultimately mean money in the bank for the company, providing the firm the capital it will need to fund the much more lucrative opportunity: NASH, or nonalcoholic steatohepatitis.


Related Content

Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger
Ocaliva OK'd; Will NASH Success, Acquisition Be Next For Intercept?
Positive Panel, But What's Ahead For Intercept's Ocaliva?
'Boring' Bodes Well For Future Of Intercept's Ocaliva


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts